AR092201A1 - - Google Patents

Info

Publication number
AR092201A1
AR092201A1 ARP130102977A AR092201A1 AR 092201 A1 AR092201 A1 AR 092201A1 AR P130102977 A ARP130102977 A AR P130102977A AR 092201 A1 AR092201 A1 AR 092201A1
Authority
AR
Argentina
Application number
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed filed Critical
Publication of AR092201A1 publication Critical patent/AR092201A1/es

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D519/00Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D471/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04Ortho-condensed systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/335Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365Lactones
    • A61K31/366Lactones having six-membered rings, e.g. delta-lactones
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/397Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having four-membered rings, e.g. azetidine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4151,2-Diazoles
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/41641,3-Diazoles
    • A61K31/41841,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/438The ring being spiro-condensed with carbocyclic or heterocyclic ring systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445Non condensed piperidines, e.g. piperocaine
    • A61K31/4523Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50Pyridazines; Hydrogenated pyridazines
    • A61K31/501Pyridazines; Hydrogenated pyridazines not condensed and containing further heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/53751,4-Oxazines, e.g. morpholine
    • A61K31/53771,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/541Non-condensed thiazines containing further heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D405/00Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D487/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04Ortho-condensed systems
ARP130102977 2012-08-22 2013-08-22 AR092201A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201261692018P 2012-08-22 2012-08-22

Publications (1)

Publication Number Publication Date
AR092201A1 true AR092201A1 (es) 2015-04-08

Family

ID=50150322

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP130102977 AR092201A1 (es) 2012-08-22 2013-08-22

Country Status (12)

Country Link
US (1) US9290517B2 (es)
EP (1) EP2888005B1 (es)
JP (1) JP2015526468A (es)
KR (1) KR20150045436A (es)
CN (1) CN104718004A (es)
AR (1) AR092201A1 (es)
AU (1) AU2013306030A1 (es)
BR (1) BR112015003109A2 (es)
CA (1) CA2881836A1 (es)
RU (1) RU2015109706A (es)
TW (1) TW201412751A (es)
WO (1) WO2014031515A1 (es)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9382243B2 (en) 2012-08-22 2016-07-05 Merck Sharp & Dohme Corp. Azabenzimidazole tetrahydropyran derivatives
EP2888008B1 (en) 2012-08-22 2018-12-26 Merck Sharp & Dohme Corp. Novel azabenzimidazole tetrahydrofuran derivatives
EP2887807B1 (en) 2012-08-22 2019-09-18 Merck Sharp & Dohme Corp. Benzimidazole hexahydrofuro[3,2-b]furan derivatives useful as amp-activated protein kinase activators
WO2014031445A1 (en) 2012-08-22 2014-02-27 Merck Sharp & Dohme Corp. Novel benzimidazole tetrahydropyran derivatives
US9540364B2 (en) 2012-08-22 2017-01-10 Merck Sharp & Dohme Corp. Benzimidazole tetrahydrofuran derivatives
JP6278472B2 (ja) 2013-02-27 2018-02-14 塩野義製薬株式会社 Ampk活性化作用を有するインドールおよびアザインドール誘導体
TR201806860T4 (tr) * 2013-07-17 2018-06-21 Boehringer Ingelheim Int Yeni azabenzimidazol türevleri.
JP6579550B2 (ja) 2014-08-27 2019-09-25 塩野義製薬株式会社 Ampk活性化作用を有するアザインドール誘導体
WO2016068099A1 (ja) 2014-10-28 2016-05-06 塩野義製薬株式会社 Ampk活性化作用を有する複素環誘導体
EP3245210B1 (en) 2015-01-16 2018-10-24 Boehringer Ingelheim International GmbH New azabenzimidazole derivatives as agonists of the amp-activated protein kinase
ES2821049T3 (es) 2015-06-18 2021-04-23 89Bio Ltd Derivados de piperidina 1,4 sustituidos
CA3014432A1 (en) 2015-06-18 2016-12-22 Cephalon, Inc. Substituted 4-benzyl and 4-benzoyl piperidine derivatives
CN105503927B (zh) * 2016-01-11 2017-04-26 沧州普瑞东方科技有限公司 一种合成3,6‑二氢‑2h‑吡(噻)喃‑4‑硼酸酯的方法
US10478425B2 (en) 2016-02-26 2019-11-19 Shionogi & Co., Ltd. 5-phenylazaindole derivative having AMPK-activating activity
JPWO2017200068A1 (ja) 2016-05-20 2019-03-22 塩野義製薬株式会社 Ampk活性化作用を有する5−置換ベンズイミダゾールおよび5−置換アザベンズイミダゾール誘導体
CN106478653B (zh) * 2016-10-16 2018-10-12 云南民族大学 异山梨醇—单咪唑盐类化合物及其制备方法
US11590161B2 (en) 2018-08-13 2023-02-28 Viscera Labs, Inc. Therapeutic composition and methods
US11524029B2 (en) 2018-08-13 2022-12-13 Viscera Labs, Inc. Therapeutic composition and methods
CN113891891A (zh) * 2019-03-05 2022-01-04 戒毒及精神健康中心 Ampa受体信号转导的调节剂
CN111423435B (zh) * 2020-03-30 2021-10-15 厦门大学 (1H-咪唑并[4,5-b]吡啶-6-基)吡啶衍生物及其应用
CA3178994A1 (en) 2020-05-19 2021-11-25 Iyassu Sebhat Ampk activators
CN116390925A (zh) * 2020-06-26 2023-07-04 卡尔优普公司 Ampk活化剂
WO2024023266A1 (en) * 2022-07-28 2024-02-01 Ac Immune Sa Novel compounds
CN115944612A (zh) * 2022-12-23 2023-04-11 敖虎山 胰高血糖素拮抗剂阿度格列凡的新用途
KR102638391B1 (ko) * 2023-05-30 2024-02-20 삼화페인트공업주식회사 다이알칸설포닐 아이소소바이드 화합물의 제조 방법, 리튬이차전지용 전해액 첨가제, 리튬이차전지용 전해액 및 리튬이차전지

Family Cites Families (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS58193541A (ja) 1982-05-07 1983-11-11 Konishiroku Photo Ind Co Ltd 熱現像画像記録材料
JPH0245181B2 (ja) 1983-03-16 1990-10-08 Fuji Photo Film Co Ltd Netsugenzokaraakankozairyo
GB8313321D0 (en) 1983-05-14 1983-06-22 Ciba Geigy Ag Preparation of mercaptan substituted carboxylic acids
GB8313320D0 (en) 1983-05-14 1983-06-22 Ciba Geigy Ag Coating compositions
GB8313322D0 (en) 1983-05-14 1983-06-22 Ciba Geigy Ag Heterocyclic-(cyclo)aliphatic carboxylic acids
PT100905A (pt) 1991-09-30 1994-02-28 Eisai Co Ltd Compostos heterociclicos azotados biciclicos contendo aneis de benzeno, ciclo-hexano ou piridina e de pirimidina, piridina ou imidazol substituidos e composicoes farmaceuticas que os contem
JPH06298731A (ja) 1993-04-13 1994-10-25 Fuji Photo Film Co Ltd 複素環化合物の製造方法
EP0710239B1 (en) * 1993-07-23 1999-02-10 Merrell Pharmaceuticals Inc. Novel 9-n-bicyclic nucleoside agents useful as selective inhibitors of proinflammatory cytokines
WO1995029897A1 (en) 1994-04-29 1995-11-09 G.D. Searle & Co. METHOD OF USING (H+/K+) ATPase INHIBITORS AS ANTIVIRAL AGENTS
AU6691498A (en) 1997-03-07 1998-09-22 Metabasis Therapeutics, Inc. Novel benzimidazole inhibitors of fructose-1,6-bisphosphatase
AU6691798A (en) 1997-03-07 1998-09-22 Metabasis Therapeutics, Inc. Novel indole and azaindole inhibitors of fructose-1,6-bisphosphatase
US6312662B1 (en) 1998-03-06 2001-11-06 Metabasis Therapeutics, Inc. Prodrugs phosphorus-containing compounds
TR200100047T2 (tr) 1998-07-15 2001-10-22 Teijin Limited Tiyobenzimidazol türevleri
WO2000014095A1 (en) 1998-09-09 2000-03-16 Metabasis Therapeutics, Inc. Novel heteroaromatic inhibitors of fructose 1,6-bisphosphatase
US20030083315A1 (en) 2000-01-17 2003-05-01 Naoki Tsuchiya Human chymase inhibitors
EP1249450B1 (en) 2000-01-17 2007-10-10 Teijin Pharma Limited Benzimidazole derivatives as human chymase inhibitors
WO2002040019A1 (fr) * 2000-11-15 2002-05-23 Banyu Pharmaceutical Co.,Ltd. Derives benzimidazoles
US7030150B2 (en) 2001-05-11 2006-04-18 Trimeris, Inc. Benzimidazole compounds and antiviral uses thereof
US20040122042A1 (en) 2001-08-24 2004-06-24 Hidenori Urata Drugs containing chymase inhibitor and ace inhibitors as the active ingredients
US7119205B2 (en) 2003-05-16 2006-10-10 Abbott Laboratories Thienopyridones as AMPK activators for the treatment of diabetes and obesity
US20060148805A1 (en) 2003-07-01 2006-07-06 Meng Hsin Chen Opthalmic compositions for treating ocular hypertension
US20070161582A1 (en) 2003-08-08 2007-07-12 Dusan Mijikovic Pharmaceutical compositions and methods for metabolic modulation
US20050148643A1 (en) 2003-08-19 2005-07-07 Agouron Pharmaceuticals, Inc. Carbamate compositions and methods fo rmodulating the activity of the CHK1 enzyme
KR20060120601A (ko) 2003-08-22 2006-11-27 데이진 화-마 가부시키가이샤 키마제 저해제를 유효 성분으로서 함유하는 약제
WO2005051298A2 (en) 2003-11-19 2005-06-09 Metabasis Therapeutics, Inc. Novel phosphorus-containing thyromimetics
WO2006094209A2 (en) 2005-03-03 2006-09-08 Sirtris Pharmaceuticals, Inc. N-benzimidazolylalkyl-substituted amide sirtuin modulators
CA2609394A1 (en) 2005-05-23 2006-11-30 Masaki Takagi Pyrazole compound and therapeutic agent for diabetes comprising the same
JP2009500351A (ja) 2005-07-04 2009-01-08 ドクター レディズ ラボラトリーズ リミテッド Ampkアクチベータとしてのチアゾール誘導体
FR2903695B1 (fr) 2006-07-13 2008-10-24 Merck Sante Soc Par Actions Si Utilisation de derives d'imidazole activateurs de l'ampk, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
MX2011003239A (es) * 2008-09-26 2011-04-28 Merck Sharp & Dohme Nuevos derivados de bencimidazol ciclicos utiles como agentes anti-diabeticos.
CA2741125A1 (en) 2008-10-22 2010-04-29 Merck Sharp & Dohme Corp. Novel cyclic benzimidazole derivatives useful anti-diabetic agents
WO2010051176A1 (en) 2008-10-29 2010-05-06 Merck Sharp & Dohme Corp. Novel cyclic benzimidazole derivatives useful anti-diabetic agents
WO2010051206A1 (en) 2008-10-31 2010-05-06 Merck Sharp & Dohme Corp. Novel cyclic benzimidazole derivatives useful anti-diabetic agents
US8895596B2 (en) 2010-02-25 2014-11-25 Merck Sharp & Dohme Corp Cyclic benzimidazole derivatives useful as anti-diabetic agents
US9133186B2 (en) * 2010-09-10 2015-09-15 Shionogi & Co., Ltd. Hetero ring-fused imidazole derivative having AMPK activating effect
EP2677869B1 (en) * 2011-02-25 2017-11-08 Merck Sharp & Dohme Corp. Novel cyclic azabenzimidazole derivatives useful as anti-diabetic agents
US9540364B2 (en) 2012-08-22 2017-01-10 Merck Sharp & Dohme Corp. Benzimidazole tetrahydrofuran derivatives
EP2888008B1 (en) 2012-08-22 2018-12-26 Merck Sharp & Dohme Corp. Novel azabenzimidazole tetrahydrofuran derivatives
WO2014031445A1 (en) 2012-08-22 2014-02-27 Merck Sharp & Dohme Corp. Novel benzimidazole tetrahydropyran derivatives
US9382243B2 (en) 2012-08-22 2016-07-05 Merck Sharp & Dohme Corp. Azabenzimidazole tetrahydropyran derivatives
EP2887807B1 (en) 2012-08-22 2019-09-18 Merck Sharp & Dohme Corp. Benzimidazole hexahydrofuro[3,2-b]furan derivatives useful as amp-activated protein kinase activators

Also Published As

Publication number Publication date
CA2881836A1 (en) 2014-02-27
TW201412751A (zh) 2014-04-01
WO2014031515A1 (en) 2014-02-27
JP2015526468A (ja) 2015-09-10
RU2015109706A (ru) 2016-10-10
CN104718004A (zh) 2015-06-17
EP2888005B1 (en) 2019-04-03
AU2013306030A1 (en) 2015-02-05
BR112015003109A2 (pt) 2017-08-15
EP2888005A1 (en) 2015-07-01
US20150284411A1 (en) 2015-10-08
EP2888005A4 (en) 2016-04-20
KR20150045436A (ko) 2015-04-28
US9290517B2 (en) 2016-03-22

Similar Documents

Publication Publication Date Title
BR112014020044A2 (es)
BR112014017635A2 (es)
BR112014019731A2 (es)
BR112014017592A2 (es)
BR112014017659A2 (es)
BR112014017646A2 (es)
BR112014017638A2 (es)
AR092201A1 (es)
BR112014017607A2 (es)
BR112013027865A2 (es)
BR112014017673A2 (es)
BR112014017644A2 (es)
BR112014018143A2 (es)
BR112014017647A2 (es)
BR112014017588A2 (es)
BR112014013184A8 (es)
BR112014017652A2 (es)
BR112014017621A2 (es)
BR112014019296A2 (es)
BR112014017641A2 (es)
BR112014017636A2 (es)
BR112014017667A2 (es)
BR112014019752A2 (es)
BR112014018051A2 (es)
BR112014017600A2 (es)

Legal Events

Date Code Title Description
FB Suspension of granting procedure